Chronic atrial fibrillation increases MicroRNA-21 in human atrial myocytes decreasing L-type calcium current

Circulation: Arrhythmia and Electrophysiology

Volumn 7, Issue 5, 2014, Pages 861-868

  Barana, Adriana ^a   Matamoros, Marcos ^a   Dolz Gaitón, Pablo ^a   Pérez Hernández, Marta ^a   Amorós, Irene ^a   Núñez, Mercedes ^a   Sacristán, Sandra ^a   Pedraz, Álvaro ^b   Pinto, Ángel ^b   Fernández Avilés, Francisco ^b   Tamargo, Juan ^a   Delpón, Eva ^a   Caballero, Ricardo ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Atrial fibrillation; Calcium channel; Human atrial myocytes; MicroRNA; MiR 21

Indexed keywords

CALCIUM CHANNEL L TYPE; MICRORNA 21; 3' UNTRANSLATED REGION; CACNA1C PROTEIN, HUMAN; CACNB2 PROTEIN, HUMAN; CALCIUM; MICRORNA; MIRN21 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ACTION POTENTIAL DURATION; ANIMAL CELL; CALCIUM CURRENT; CHO CELL LINE; GENE EXPRESSION; GENETIC TRANSFECTION; HEART ATRIUM FIBRILLATION; HEART MUSCLE CELL; HUMAN; LUCIFERASE ASSAY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM; ACTION POTENTIAL; AGED; ATRIAL FIBRILLATION; BINDING SITE; CHRONIC DISEASE; DOWN REGULATION; FEMALE; GENETICS; HEART ATRIUM APPENDAGE; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; REPORTER GENE; TIME; UPREGULATION;

3' UNTRANSLATED REGIONS; ACTION POTENTIALS; AGED; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; BINDING SITES; CALCIUM; CALCIUM CHANNELS, L-TYPE; CHRONIC DISEASE; DOWN-REGULATION; FEMALE; GENES, REPORTER; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MYOCYTES, CARDIAC; TIME FACTORS; TRANSFECTION; UP-REGULATION;

EID: 84912532960     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.114.001709     Document Type: Review

References (35)

1. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265-325.
2. Wakili R, Voigt N, Kääb S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011;121:2955-2968.
3. Van Wagoner DR, Pond AL, Lamorgese M, Rossie SS, McCarthy PM, Nerbonne JM. Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res. 1999;85:428-436.
4. Yue L, Melnyk P, Gaspo R, Wang Z, Nattel S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res. 1999;84:776-784.
5. Caballero R, de la Fuente MG, Gómez R, Barana A, Amorós I, Dolz- Gaitón P, Osuna L, Almendral J, Atienza F, Fernández-Avilés F, Pita A, Rodríguez-Roda J, Pinto A, Tamargo J, Delpón E. In humans, chronic atrial fibrillation decreases the transient outward current and ultrarapid component of the delayed rectifier current differentially on each atria and increases the slow component of the delayed rectifier current in both. J Am Coll Cardiol. 2010;55:2346-2354.
6. Brundel BJ, Van Gelder IC, Henning RH, Tieleman RG, Tuinenburg AE, Wietses M, Grandjean JG, Van Gilst WH, Crijns HJ. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation. 2001;103:684-690.
7. Christ T, Boknik P, Wöhrl S, Wettwer E, Graf EM, Bosch RF, Knaut M, Schmitz W, Ravens U, Dobrev D. L-type Ca2+ current downregulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. Circulation. 2004;110:2651-2657.
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
9. Rau F, Freyermuth F, Fugier C, Villemin JP, Fischer MC, Jost B, Dembele D, Gourdon G, Nicole A, Duboc D, Wahbi K, Day JW, Fujimura H, Takahashi MP, Auboeuf D, Dreumont N, Furling D, Charlet-Berguerand N. Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. Nat Struct Mol Biol. 2011;18:840-845.
10. Lu Y, Zhang Y, Wang N, Pan Z, Gao X, Zhang F, Zhang Y, Shan H, Luo X, Bai Y, Sun L, Song W, Xu C, Wang Z, Yang B. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation. 2010;122:2378-2387.
11. Liu Z, Zhou C, Liu Y, Wang S, Ye P, Miao X, Xia J. The expression levels of plasma micoRNAs in atrial fibrillation patients. PLoS One. 2012;7:e44906.
12. Adam O, Löhfelm B, Thum T, Gupta SK, Puhl SL, Schäfers HJ, Böhm M, Laufs U. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol. 2012;107:278.
13. Dobrev D. Is altered atrial microRNA-ome a critical contributor to the pathophysiology of atrial fibrillation? Basic Res Cardiol. 2012;107:284.
14. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456:980-984.
15. Cardin S, Guasch E, Luo X, Naud P, Le Quang K, Shi Y, Tardif JC, Comtois P, Nattel S. Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ Arrhythm Electrophysiol. 2012;5:1027-1035.
16. González de la Fuente M, Barana A, Gómez R, Amorós I, Dolz-Gaitón P, Sacristán S, Atienza F, Pita A, Pinto Á, Fernández-Avilés F, Caballero R, Tamargo J, Delpón E. Chronic atrial fibrillation up-regulates β1- Adrenoceptors affecting repolarizing currents and action potential duration. Cardiovasc Res. 2013;97:379-388.
17. Müller D, Katinger H, Grillari J. MicroRNAs as targets for engineering of CHO cell factories. Trends Biotechnol. 2008;26:359-365.
18. Humphreys DT, Hynes CJ, Patel HR, Wei GH, Cannon L, Fatkin D, Suter CM, Clancy JL, Preiss T. Complexity of murine cardiomyocyte miRNA biogenesis, sequence variant expression and function. PLoS One. 2012;7:e30933.
19. Cheng Y, Zhang C. MicroRNA-21 in cardiovascular disease. J Cardiovasc Transl Res. 2010;3:251-255.
20. Nishi H, Sakaguchi T, Miyagawa S, Yoshikawa Y, Fukushima S, Saito S, Ueno T, Kuratani T, Sawa Y. Impact of microRNA expression in human atrial tissue in patients with atrial fibrillation undergoing cardiac surgery. PLoS One. 2013;8:e73397.
21. Cooley N, Cowley MJ, Lin RC, Marasco S, Wong C, Kaye DM, Dart AM, Woodcock EA. Influence of atrial fibrillation on microRNA expression profiles in left and right atria from patients with valvular heart disease. Physiol Genomics. 2012;44:211-219.
22. Zhao Z, Liu T, Wang X, Li G. MicroRNAs as novel antiarrhythmic targets for atrial fibrillation. Int J Cardiol. 2013;168:e135-e137.
23. Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA- 21 in health and disease. RNA Biol. 2011;8:706-713.
24. Gao G, Dudley SC Jr. Redox regulation, NF-kappaB, and atrial fibrillation. Antioxid Redox Signal. 2009;11:2265-2277.
25. Wei C, Li L, Kim IK, Sun P, Gupta S. NF-κB mediated miR-21 regulation in cardiomyocytes apoptosis under oxidative stress. Free Radic Res. 2014;48:282-291.
26. Carrillo ED, Escobar Y, González G, Hernández A, Galindo JM, García MC, Sánchez JA. Posttranscriptional regulation of the β2-subunit of cardiac L-type Ca2+ channels by MicroRNAs during long-term exposure to isoproterenol in rats. J Cardiovasc Pharmacol. 2011;58:470-478.
27. Buraei Z, Yang J. The ß subunit of voltage-gated Ca2+ channels. Physiol Rev. 2010;90:1461-1506.
28. Wakili R, Yeh YH, Yan Qi X, Greiser M, Chartier D, Nishida K, Maguy A, Villeneuve LR, Boknik P, Voigt N, Krysiak J, Kääb S, Ravens U, Linke WA, Stienen GJ, Shi Y, Tardif JC, Schotten U, Dobrev D, Nattel S. Multiple potential molecular contributors to atrial hypocontractility caused by atrial tachycardia remodeling in dogs. Circ Arrhythm Electrophysiol. 2010;3:530-541.
29. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation. 1996;94:2968-2974.
30. Cunha SR, Hund TJ, Hashemi S, Voigt N, Li N, Wright P, Koval O, Li J, Gudmundsson H, Gumina RJ, Karck M, Schott JJ, Probst V, Le Marec H, Anderson ME, Dobrev D, Wehrens XH, Mohler PJ. Defects in ankyrinbased membrane protein targeting pathways underlie atrial fibrillation. Circulation. 2011;124:1212-1222.
31. Greiser M, Halaszovich CR, Frechen D, Boknik P, Ravens U, Dobrev D, Lückhoff A, Schotten U. Pharmacological evidence for altered src kinase regulation of I (Ca,L) in patients with chronic atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol. 2007;375:383-392.
32. Girmatsion Z, Biliczki P, Bonauer A, Wimmer-Greinecker G, Scherer M, Moritz A, Bukowska A, Goette A, Nattel S, Hohnloser SH, Ehrlich JR. Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm. 2009;6:1802-1809.
33. Luo X, Pan Z, Shan H, Xiao J, Sun X, Wang N, Lin H, Xiao L, Maguy A, Qi XY, Li Y, Gao X, Dong D, Zhang Y, Bai Y, Ai J, Sun L, Lu H, Luo XY, Wang Z, Lu Y, Yang B, Nattel S. MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest. 2013;123:1939-1951.
34. Kaur K, Zarzoso M, Ponce-Balbuena D, Guerrero-Serna G, Hou L, Musa H, Jalife J. TGF-β1, released by myofibroblasts, differentially regulates transcription and function of sodium and potassium channels in adult rat ventricular myocytes. PLoS One. 2013;8:e55391.
35. Musa H, Kaur K, O'Connell R, Klos M, Guerrero-Serna G, Avula UM, Herron TJ, Kalifa J, Anumonwo JM, Jalife J. Inhibition of platelet-derived growth factor-AB signaling prevents electromechanical remodeling of adult atrial myocytes that contact myofibroblasts. Heart Rhythm. 2013;10:1044-1051.